Amyloidosis
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Challenges in ATTR Amyloidosis: An Expert Debate
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM